Latest Janus kinase inhibitor Stories
- 68% transfusion independence response rate and 37% durable spleen response rate - MISSISSAUGA, ON, Dec. 9, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM) today reported updated results from the 166 patient Phase I/II study of its JAK1/JAK2 inhibitor, CYT387, for the treatment of myelofibrosis. The results were presented this afternoon in an oral session at the 54(th) Annual Meeting of the American Society of Hematology underway in Atlanta, Georgia....
PARIS, Dec. 9, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today new Phase II data showing that treatment with a novel, investigational, selective JAK2 inhibitor (SAR302503) reduced spleen size and improved constitutional symptoms in patients with intermediate-2 or high-risk primary or secondary myelofibrosis (MF), a hematologic malignancy with unmet medical needs. The data were presented today during the 2012 Annual Meeting of the American Society of...
LA JOLLA, Calif., Nov. 15, 2012 /PRNewswire/ -- Auspex Pharmaceuticals, Inc. today announced that it has been granted U.S. Patent No. 8,299,084 covering the company's novel JAK kinase inhibitor SD-900, a deuterium-substituted analogue of tofacitinib. "The issuance of a composition-of-matter patent for SD-900 is strong validation of Auspex's technological approach to the creation of important new drugs," said Lawrence C. Fritz, Ph.D., President and Chief Executive Officer of...
WASHINGTON, Nov. 13, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) today announced 24-week results from the continuation of an ongoing Phase IIb study of baricitinib, an orally available janus kinase (JAK) inhibitor, in patients with moderate-to-severe rheumatoid arthritis (RA) who had an inadequate response to treatment with methotrexate. Additionally, Magnetic Resonance Imaging (MRI) technology was used in a sub-study to examine the...
INDIANAPOLIS, Nov. 9, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present Phase II data in rheumatoid arthritis (RA) for two of its investigational autoimmune medicines at the annual meeting of the American College of Rheumatology (ACR), which takes place Nov. 10-14, 2012, in Washington, D.C. These compounds include tabalumab, an anti-BAFF monoclonal antibody, and baricitinib, a janus kinase (JAK) inhibitor being developed in partnership with Incyte Corporation. The...
MISSISSAUGA, ON, Nov. 5, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM), a drug development company advancing hematology and cancer related products, today reported interim results from the Phase I/II study of CYT387, a JAK1/JAK2 inhibitor currently being evaluated for the treatment of myelofibrosis, which were included in an abstract submitted to the American Society of Hematology in August 2012. Updated results will be presented in an Oral Session at the 2012...
SEATTLE, Oct. 15, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that CT-1578's (previously known as SB-1578) unique kinase spectrum that selectively inhibits JAK2 over JAK1 or JAK3, coupled with its inhibition of FLT-3 and c-Fms, produced potency in not only preventing the development of rheumatoid arthritis ("RA"), but also in its treatment and reversal of bone and joint destruction after the onset of RA in preclinical models according...
HORSHAM, Pa., Oct. 1, 2012 /PRNewswire/ -- Janssen Biotech, Inc. ("Janssen") announced today that it has entered into a license agreement with Astellas Pharma Inc. ("Astellas") for the worldwide development and commercialization, except in Japan, of ASP015K, an oral, small molecule Janus Kinase (JAK) inhibitor. ASP015K is currently in Phase 2b development as a once-daily oral treatment for moderate-to-severe rheumatoid arthritis (RA), following a successful Phase 2a study...
SEATTLE, Sept. 24, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the phase 1 study data of its highly selective oral JAK2 inhibitor pacritinib, or SB1518, showed encouraging anti-tumor activity and good tolerability in 34 patients with relapsed/refractory lymphoma. The results were published online in the Journal of Clinical Oncology in September, 2012. Thirty-four patients received daily oral doses of pacritinib ranging from...
